An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Pegcantratinib (Primary) ; Calcipotriol
- Indications Plaque psoriasis; Pruritus; Psoriasis
- Focus Therapeutic Use
- Sponsors Sienna Biopharmaceuticals
- 16 Jan 2019 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Mar 2018 New trial record